ReviewPathogens (Basel, Switzerland)2021
Potential SARS-CoV-2 Immune Correlates of Protection in Infection and Vaccine Immunization.
Review in Pathogens (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 66 citations in OpenAlex.
- Long-term immunity and protection against SARS-CoV-2 XBB.1.5 following homologous and heterologous mRNA and MVA vaccination.Frontiers in immunology · 2026Article
- COVID-19 Vaccination and Infection: Effect on Maternal and Cord Blood Antibody Levels at Delivery.Journal of obstetrics and gynaecology of India · 2025Article
- COVID-19 pneumonia in lung transplant recipients: understanding risk factors and treatment outcomes in Japan.Clinical and experimental medicine · 2024Article
- Immune responses to SARS-CoV-2 mRNA vaccination in people with idiopathic CD4 lymphopenia.The Journal of allergy and clinical immunology · 2024Article
- Article
- Sex-biased immunogenicity of a mucosal subunit vaccine against SARS-CoV-2 in mice.Frontiers in immunology · 2024Article
- Immunogenicity studies of recombinant RBD SARS-CoV-2 as a COVID-19 vaccine candidate produced inVaccine: X · 2024Article
- Image-based and machine learning-guided multiplexed serology test for SARS-CoV-2.Cell reports methods · 2023Article
- RDE Treatment Prevents Non-Specific Detection of SARS-CoV-2- and Influenza-Specific IgG Antibodies in Heat-Inactivated Serum Samples.Antibodies (Basel, Switzerland) · 2023Article
- A SARS-CoV-2 Vaccine Designed for Manufacturability Results in Unexpected Potency and Non-Waning Humoral Response.Vaccines · 2023Article
- Third dose of an mRNA COVID-19 vaccine for patients with multiple myeloma.Clinical infection in practice · 2023Article
- Convalescent human IgG, but not IgM, from COVID-19 survivors confers dose-dependent protection against SARS-CoV-2 replication and disease in hamsters.Frontiers in immunology · 2023Article
- Protection from COVID-19 disease in hamsters vaccinated with subunit SARS-CoV-2 S1 mucosal vaccines adjuvanted with different adjuvants.Frontiers in immunology · 2023Article
- Amphiphile-CpG vaccination induces potent lymph node activation and COVID-19 immunity in mice and non-human primates.NPJ vaccines · 2022Article
- SARS-CoV-2-The Role of Natural Immunity: A Narrative Review.Journal of clinical medicine · 2022Review
- An Algae-Made RBD from SARS-CoV-2 Is Immunogenic in Mice.Pharmaceuticals (Basel, Switzerland) · 2022Article
- SARS-CoV-2 Antibody Response against Mild-to-Moderate Breakthrough COVID-19 in Home Isolation Setting in Thailand.Vaccines · 2022Article
- An intranasally administrated SARS-CoV-2 beta variant subunit booster vaccine prevents beta variant replication in rhesus macaques.PNAS nexus · 2022Article
- In vitro study on efficacy of PHELA, an African traditional drug against SARS-CoV-2.Scientific reports · 2022Article
- How to Evaluate COVID-19 Vaccine Effectiveness-An Examination of Antibody Production and T-Cell Response.Diagnostics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Both SARS-CoV-2 infections and vaccines induce robust immune responses. Current data suggested that high neutralizing antibody titers with sustained Th1 responses might correlate with protection against viral transmission and disease development and severity. In addition, genetic and innate immune factors, including higher levels of type I interferons, as well as the induction of trained immunity and local mucosal immunity also contribute to lower risk of infection and amelioration of disease severity. The identification of immune correlates of protection will facilitate the development of effective vaccines and therapeutics strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.